Pay in 4 interest-free payments of $5.81 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
These risks and others described in the Risk Factors section of each of our most recently filed Quarterly Report on Form 10-Q, our most recently filed Annual Report on Form 10-K, and any of our subsequent filings with the Commission may not be exhaustive
Many report feeling fuller sooner and more satisfied with smaller meals
It has also been examined in preclinical work focused on neuroprotection and cerebral circulation
These reactions are usually mild and go away on their own
Agency review: FDA evaluates the New Drug Application (NDA)
Aardvark Therapeutics Sector: Oral gut-restricted bitter taste receptor agonists for hunger suppression HQ: San Diego, CA Year Founded: 2017 Origin Story: Aardvark Therapeutics was founded around a mechanistically distinct hypothesis: rather than suppressing appetite like GLP-1 drugs, the companys lead compound activates bitter taste receptors (TAS2Rs) confined to the gastrointestinal tract to trigger local release of satiety hormones, targeting hunger itself without systemic drug exposure
US$ 25.96
US$ 26.80
US$ 22.48
US$ 26.47
US$ 21.17
US$ 25.15
US$ 27.03
US$ 24.27
US$ 25.45
US$ 27.37
